Kerrisdale Advisers, LLC Pro Qr Therapeutics N.V. Transaction History

Kerrisdale Advisers, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.9 - $8.39 $14,306 - $133,367	-15,896 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$6.58 - $8.44 $2.88 Million - $3.69 Million	-437,286 Reduced 96.49%	15,896 $127,000
Q4 2020 Feb 16, 2021	BUY	$3.58 - $4.85 $1.62 Million - $2.2 Million	453,182 New	453,182 $1.9 Million
Q3 2020 Nov 16, 2020	SELL	$4.79 - $6.3 $2.17 Million - $2.86 Million	-453,182 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$4.5 - $6.53 $24,862 - $36,078	5,525 Added 1.23%	453,182 $2.76 Million
Q1 2020 May 15, 2020	SELL	$5.25 - $9.9 $6,420 - $12,107	-1,223 Reduced 0.27%	447,657 $2.46 Million
Q4 2019 Feb 14, 2020	SELL	$5.84 - $10.51 $97,528 - $175,517	-16,700 Reduced 3.59%	448,880 $4.45 Million
Q2 2019 Aug 14, 2019	BUY	$9.1 - $15.55 $3.66 Million - $6.25 Million	401,900 Added 631.12%	465,580 $4.24 Million
Q1 2019 May 15, 2019	BUY	$12.5 - $18.48 $796,000 - $1.18 Million	63,680 New	63,680 $883,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $157M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Kerrisdale Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Kerrisdale Advisers, LLC with notifications on news.